← Evidence map

TrialThe Journal of urology2026

UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial.

Sandip M Prasad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

Not cited yet

The trial

NCT05243550phase 3240 enrolled2022

UGN-102 for Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION Trial. | Socratic